Glenmark Pharmaceuticals Ltd 532296
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Glenmark Pharmaceuticals and South Piedmont Community College Launch Aseptic Training Facility in Monroe, N.C.
-
Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
-
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan — Update
-
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 282.22M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 23.83
- Price/Sales
- 3.75
- Dividend Yield (Trailing)
- 0.21%
- Dividend Yield (Forward)
- 0.21%
- Dividend Payment Schedule
- Sep, Oct
- Total Yield
- 0.21%
Company Profile
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Growth
- Total Number of Employees
- 16,946
- Website
- https://www.glenmarkpharma.com
Valuation
|
Metric
|
532296
|
|---|---|
Price/Earnings (Normalized) | 23.83 |
Price/Book Value | 6.29 |
Price/Sales | 3.75 |
Price/Cash Flow | 17.92 |
Price/Earnings
532296
Financial Strength
|
Metric
|
532296
|
|---|---|
Quick Ratio | 1.11 |
Current Ratio | 1.77 |
Interest Coverage | 13.38 |
Quick Ratio
532296
Profitability
|
Metric
|
532296
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
532296
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|g?KH$v<# | LOCK|bjYn | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|hBRm@$#n | LOCK|%Kh<f | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|C^#&W# | LOCK|H% | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|ws%h^xP | LOCK|m& | $29B | |||
| Viatris Inc
VTRS
| LOCK|lS&K>h | LOCK|%&X | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|H%C | LOCK|%KN | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|ggCMJTd | LOCK|s>R | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|f#!?Xh! | LOCK|!?y | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|q&?&N^ | LOCK|VhlT | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|JKR#^fp | LOCK|@l | $2B |
United States